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Abstract Diverse human disorders, including several neurode-
generative diseases and systemic amyloidosis, are thought to
arise from the misfolding and aggregation of an underlying
protein. Recent findings strongly support this hypothesis and
have increased our understanding of the molecular mechanism of
protein conformational disorders. Many questions are still
pending, but the data overall suggest that correction of protein
misfolding constitutes a viable therapeutic strategy for con-
formational diseases. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The biological function of a protein depends on its tridi-
mensional structure, which is determined by its amino acid
sequence during the process of protein folding. In the last
few years, diverse diseases have been shown to arise from
protein misfolding and are now grouped together under the
name of protein conformational disorders (PCDs) [1^5]. This
group includes Alzheimer’s disease (AD), transmissible spon-
giform encephalopathies (TSEs), serpin-de¢ciency disorders,
haemolytic anemia, Huntington disease (HD), cystic ¢brosis,
diabetes type II, amyotrophic lateral sclerosis (ALS), Parkin-
son disease (PD), dialysis-related amyloidosis and more than
15 other less well-known diseases (Table 1).
The hallmark event in PCD is a change in the secondary
and/or tertiary structure of a normal protein without altera-
tion of the primary structure. The conformational change may
promote the disease by either gain of a toxic activity or by the
lack of biological function of the natively folded protein [3,5]
(Fig. 1). There is no evident sequence or structural homology
among the proteins implicated in PCD. However, the striking
feature of these proteins is their inherent ability to adopt at
least two di¡erent stable conformations [5]. In most of PCDs
the misfolded protein is rich in L-sheet conformation [4,5]. L-
Sheets are one of the prevalent, repetitive secondary structures
in folded proteins and are formed of alternating peptide
pleated strands linked by hydrogen bonding between the
NH and CO groups of the peptide bond. While in K-helices
the hydrogen bonds are between groups within the same
strand, in L-sheets the bonds are between one strand and
another. Since the second L-strand can come from a di¡erent
region of the same protein or from a di¡erent molecule, for-
mation of L-sheets is usually stabilized by protein oligomeri-
zation or aggregation. Indeed, in most PCDs the misfolded
protein self-associates and becomes deposited in amyloid-like
aggregates in diverse organs, inducing tissue damage and or-
gan dysfunction [2] (Fig. 1).
2. Role of protein misfolding and aggregation in disease
Neuropathologic and genetic studies as well as the develop-
ment of transgenic animal models have provided strong evi-
dences for the involvement of protein misfolding in disease.
Almost 100 years ago, the neuropathologist Alois Alzheimer
described for the ¢rst time the typical aggregates in the brain
parenchyma of demented people [6]. We now know that these
aggregates, called amyloid plaques, are composed of protein
¢brils. With the exception of cystic ¢brosis and some forms of
TSE, the end point of protein misfolding in PCD is aberrant
protein aggregation and accumulation as amyloid-like depos-
its in diverse organs [2,3,7^9]. The correlation and co-local-
ization of protein aggregates with degenerating tissue and dis-
ease symptoms is a strong indication of the involvement of
amyloid deposition in the pathogenesis of PCD [7^9]. More-
over, protein deposits have become a typical signature of PCD
and their presence is used for de¢nitive diagnosis [10,11].
However, it is still a matter of controversy whether the depos-
its of aggregated protein are the culprit of the disease or an
inseparable epiphenomenon [5,12^14].
Another important piece of evidence for the role of protein
misfolding in disease comes from genetic studies [2,15^19].
Most PCDs have both an inherited and sporadic origin. In-
terestingly, mutations in the genes encoding the protein com-
ponent of ¢brillar aggregates are genetically associated with
inherited forms of the disease. The familial forms usually have
an earlier onset and higher severity than sporadic cases. In the
familial cases, a mutation may destabilize the normal protein
folding, favoring the misfolding and aggregation of the pro-
tein. Mutations in the respective ¢brillar proteins have been
associated with familial forms of many diseases, including
AD, TSE, HD and related polyglutamine disorders, PD, amy-
loid polyneuropathy, cardiac amyloidosis, visceral amyloido-
sis, cerebral hemorrhage with amyloidosis of the Dutch and
Icelandic type, cerebral amyloidosis of the British and Dan-
nish type, thromboembolic disease, angioedema, emphysema,
sickle cell anemia and ALS [2,15^18].
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Studies with transgenic animal models have been useful in
understanding the contribution of the misfolded protein in
disease pathogenesis [19^25]. Several pathological features of
diverse PCDs have been induced in animals by incorporation
of the human mutated gene for the protein undergoing mis-
folding. Transgenic mice that overexpress high levels of hu-
man amyloid precursor protein containing diverse mutations
progressively develop many of the pathological hallmarks of
AD, including cerebral amyloid deposits, neuritic dystrophy,
astrogliosis, neuronal loss and cognitive and behavioral alter-
ations [19,23,26,27]. ALS pathology has been produced in
mice by overexpressing the human mutated superoxide dismu-
tase (SOD) gene [19,28]. Some of these mice develop motor
neuron dysfunction similar to ALS patients, and typical
pathological alterations, including the presence of hyaline in-
clusion bodies in degenerating axons, muscle atrophy and
wasting, astrocytes damage and extensive loss of large mye-
linated axons of motor neuronal cells. Recently, it was re-
ported that transgenic mice expressing the wild-type human
K-synuclein gene developed several of the clinico-pathological
features of PD, including accumulation of Lewy bodies in
neurons of the neocortex, hippocampus and substantia nigra,
loss of dopaminergic terminals in the basal ganglia and asso-
ciated motor impairments [29]. Transgenic mice containing
the exon 1 of the human huntingtin and carrying 115^156
CAG repeat expansions develop pronounced neuronal intra-
nuclear inclusions, containing the proteins huntingtin and
ubiquitin, prior to developing a neurological phenotype [30].
The cerebral abnormalities were strikingly similar to those
observed in HD patients. In addition, these mice develop a
progressive neurological dysfunction with a movement disor-
der and weight loss similar to HD [31]. One of the ¢rst trans-
genic models showing a neurodegenerative process similar to a
human disease was made by overexpression of the human
mutated prion protein (PrP) gene [25,32]. Spontaneous neuro-
logic disease with spongiform degeneration developed and
these abnormalities have been transmitted to non-transgenic
mice by inoculation of the sick brain homogenate. Finally, a
transgenic mouse model with high rates of expression of hu-
man islet amyloid polypeptide (IAPP) spontaneously devel-
oped diabetes mellitus by 8 weeks of age, which was associ-
ated with selective L-cell death and impaired insulin secretion
[24]. Small intra- and extracellular IAPP aggregates were
present in islets of transgenic mice during the development
of diabetes mellitus.
The generation of animal models showing clinical and
pathological features similar to the disease by expressing the
human protein involved in abnormal folding and aggregation
strongly supports a critical role for protein misfolding and
polymerization in the disease. However, temporal studies of
the appearance of disease-like features in some of the trans-
genic models have shown that signi¢cant tissue damage and
clinical symptoms appear before detection of protein aggre-
gates [24,26,33]. These ¢ndings suggest that a misfolded solu-
ble intermediate, not yet deposited in the tissue, could be the
real culprit of the PCD pathogenesis [5,12^14]. In this scenar-
io, the formation of large protein aggregates deposited in the
tissue could even be considered a protective event that allows
the deposition and isolation of the toxic abnormally folded
proteins.
3. Protein misfolding and aggregation: which comes ¢rst?
Protein misfolding is dependent upon conformational
changes, which could be induced, stabilized or independent
of protein oligomerization. The starting point in PCD is the
natural protein folded in the native and active conformation
which is usually a mixture of K-helical and random structure,
and the end point is the same protein aggregated and adopt-
ing a L-pleated sheet conformation. It is unclear at present
whether the misfolding triggers protein aggregation or rather
protein oligomerization induces the conformational changes
(Fig. 2). The latter is not a purely academic debate, but it is
very relevant for the design of e¡ective therapeutic strategies.
Based on kinetic modeling of protein aggregation, it has
been proposed that the critical event in PCD is the formation
of protein oligomers that act as seeds to induce protein mis-
folding [34^36] (Fig. 2A). In this model, misfolding occurs as
a consequence of protein aggregation (polymerization hypoth-
esis), which follows a crystallization-like process dependent
upon nucleus formation [34,35]. A nucleation-dependent poly-
merization process is characterized by a slow lag phase in
which a series of unfavorable interactions occur to form an
oligomeric nucleus that rapidly grows to form larger polymers
[35] (Fig. 2A). The lag phase can be minimized or removed by
Table 1
List of some diseases that have been classi¢ed in the group of
PCDs [2^5]
Protein involved Diseases
Amyloid-L AD
K-Synuclein PD
Amylin Diabetes type 2
SOD ALS
L2-Microglobulin Haemodialysis-related amyloidosis
Amyloid-A Reactive amyloidosis
CFTR protein Cystic ¢brosis
Hemoglobin Sickle cell anemia
Huntingtin HD
PrP Creutzfeldt^Jakob disease and related
disorders
Ten other proteins Systemic and cerebral heriditary
amyloidosis
Fig. 1. Protein misfolding and disease. A conformational change in
a normal protein seems to be the hallmark event in a group of di-
verse diseases. Protein misfolding may be associated to disease by
either the absence of biological activity of the folded protein or by
a gain of toxic activity by the misfolded protein. Aggregation of the
misfolded protein may also contribute to the disease pathogenesis.
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addition of pre-formed nucleus or seeds. This hypothesis has a
precedent in normal protein polymerization processes, such as
microtubule formation.
The alternative model is that the underlying protein is sta-
ble in both the folded and misfolded forms in solution [3,37^
40] (conformational hypothesis). This hypothesis proposes
that spontaneous or induced conformational changes result
in the formation of the misfolded protein that may or may
not aggregate (Fig. 2B). In this model, the formation of amy-
loid is a non-necessary end point of the conformational
change, which can be an accompanying consequence rather
than a direct cause of the disease [5,37,40]. A central issue in
the conformational hypothesis is the identi¢cation of the fac-
tors inducing the protein structural changes. Over the last few
years, several factors have been described to play such a role
[40,41], including mutations that destabilize the folded struc-
ture, modi¢cation on the environmental conditions (pH, oxi-
dative stress, metal ions) and the activity of certain proteins
collectively named pathological chaperones (apolipoprotein E,
amyloid P component, protein X).
An intermediate view (Fig. 2C) is that slight conformational
changes result in the formation of an amyloidogenic inter-
mediate, which is unstable in an aqueous environment because
of exposure of hydrophobic segments to the solvent (confor-
mation/oligomerization hypothesis) [2,5,42,43]. This unstable
intermediate is stabilized by intermolecular interactions with
other molecules forming small L-sheet oligomers, which by
further growth produce amyloid ¢brils [2,42,43]. In this model
the conversion of the folded protein into the pathological
form is triggered by structural changes, but complete misfold-
ing is dependent upon oligomerization. The presence of some
degree of conformational changes prior to the formation of
aggregates has been demonstrated for diverse proteins includ-
ing transthyretin, serpins, amyloid-L and PrP [2,4,5,42].
The three models explain in variable degree most of the
experimental results. However, it appears that the conforma-
tion/oligomerization hypothesis is the most comprehensive
and accepted model of protein misfolding and aggregation.
4. Correcting protein misfolding as a novel therapeutic
approach
Considering that protein misfolding and aggregation are
central in the pathogenesis of PCD, a therapy directed to
the cause of the disease should aim to inhibit and/or reverse
the conformational changes that result in the formation of the
pathological protein conformer.
Assuming that protein misfolding is triggered by conforma-
tional changes stabilized by protein oligomerization, an inter-
esting strategy would be to preclude the stabilization of the
misfolding or better to destabilize the monomeric intermediate
and the early L-sheet oligomers. We have postulated that
short synthetic peptides containing the self-recognition motif
of the protein and engineered to destabilize the abnormal
conformation might be useful to correct protein misfolding
[4,12,43]. These peptides called synthetic mini-chaperones are
designed to be similar to the sequence of the protein region
responsible for self-association and contain residues that spe-
ci¢cally favor or disfavor a particular structural motif [4,43].
Considering that in most PDCs the misfolded protein is rich
in L-sheet structure, we have focused mainly on the design of
peptides to prevent and to reverse L-sheet formation (L-sheet
breaker peptides) [43].
L-Sheet breaker peptides have, so far, been designed for
blocking the conformational changes and aggregation under-
gone by both AL and PrP [4,43^45]. We have reported that
11- and 5-residue L-sheet breaker peptides, homologous to the
central hydrophobic region of AL, inhibited and dissolved
amyloid aggregates in vitro and in animal models of AD
[44,46]. Furthermore, the 5-amino acid peptide prevented neu-
ronal damage induced by amyloid both in cell culture and in a
disease animal model [44,46]. Based on the same concept and
using the PrP sequence 114^122 as a template, we have also
produced L-sheet breaker peptides for the treatment of TSE
[45]. Several in vitro, cell culture and in vivo assays were used
to test the activity of the peptides and the results clearly in-
dicate that it is possible not only to prevent the PrPcCPrPsc
conversion, but more interestingly to reverse the infectious
Fig. 2. Models for the molecular mechanism of protein misfolding
and aggregation. Three di¡erent hypotheses have been proposed to
describe the relationship between conformational changes and aggre-
gation. In the polymerization hypothesis (A), aggregation induces
the protein conformational changes, while in the conformational hy-
pothesis (B), protein misfolding is independent of aggregation,
which is a non-necessary end point of conformational changes. The
conformation/oligomerization model (C) represents an intermediate
view in which slight conformational changes trigger oligomerization
that is essential for the stabilization of protein misfolding. Square
represents the folded native conformation, circles the disease-associ-
ated conformer and pentagon corresponds to an unstable conforma-
tional intermediate.
FEBS 24911 5-6-01 Cyaan Magenta Geel Zwart
C. Soto/FEBS Letters 498 (2001) 204^207206
PrPsc conformer to a biochemical and structural state similar
to PrPc [45].
These results together support the notion that synthetic L-
sheet breaker peptides might be useful in destabilizing the L-
sheet rich abnormal conformation, inducing its conversion
into the normal form. Synthetic mini-chaperone peptides do
not need to be restricted to breaking L-sheets [4,43]. Peptides
can also be engineered to act as L-sheet promoters, K-helical
breakers, L-turn promoters or even to induce a desired con-
formation in unstructured protein fragments. The principles
to manipulate protein conformation may provide a general
platform technology to design drugs for the treatment of
PDC. Moreover, our ¢ndings suggesting that protein confor-
mation can indeed be speci¢cally altered open a new approach
for modifying phenotypic characteristics by modulating exper-
imentally the structure of a selected protein. Therefore, the
discovery of the principles for generating synthetic mini-chap-
erones could be useful as a novel therapeutic approach for
disorders where the function of a protein needs to be modi-
¢ed.
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